Cargando…
Novel Peptide Therapeutic Approaches for Cancer Treatment
Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616177/ https://www.ncbi.nlm.nih.gov/pubmed/34831131 http://dx.doi.org/10.3390/cells10112908 |
_version_ | 1784604284684337152 |
---|---|
author | Li, Caroline M. Haratipour, Pouya Lingeman, Robert G. Perry, J. Jefferson P. Gu, Long Hickey, Robert J. Malkas, Linda H. |
author_facet | Li, Caroline M. Haratipour, Pouya Lingeman, Robert G. Perry, J. Jefferson P. Gu, Long Hickey, Robert J. Malkas, Linda H. |
author_sort | Li, Caroline M. |
collection | PubMed |
description | Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer. |
format | Online Article Text |
id | pubmed-8616177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86161772021-11-26 Novel Peptide Therapeutic Approaches for Cancer Treatment Li, Caroline M. Haratipour, Pouya Lingeman, Robert G. Perry, J. Jefferson P. Gu, Long Hickey, Robert J. Malkas, Linda H. Cells Review Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer. MDPI 2021-10-27 /pmc/articles/PMC8616177/ /pubmed/34831131 http://dx.doi.org/10.3390/cells10112908 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Caroline M. Haratipour, Pouya Lingeman, Robert G. Perry, J. Jefferson P. Gu, Long Hickey, Robert J. Malkas, Linda H. Novel Peptide Therapeutic Approaches for Cancer Treatment |
title | Novel Peptide Therapeutic Approaches for Cancer Treatment |
title_full | Novel Peptide Therapeutic Approaches for Cancer Treatment |
title_fullStr | Novel Peptide Therapeutic Approaches for Cancer Treatment |
title_full_unstemmed | Novel Peptide Therapeutic Approaches for Cancer Treatment |
title_short | Novel Peptide Therapeutic Approaches for Cancer Treatment |
title_sort | novel peptide therapeutic approaches for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616177/ https://www.ncbi.nlm.nih.gov/pubmed/34831131 http://dx.doi.org/10.3390/cells10112908 |
work_keys_str_mv | AT licarolinem novelpeptidetherapeuticapproachesforcancertreatment AT haratipourpouya novelpeptidetherapeuticapproachesforcancertreatment AT lingemanrobertg novelpeptidetherapeuticapproachesforcancertreatment AT perryjjeffersonp novelpeptidetherapeuticapproachesforcancertreatment AT gulong novelpeptidetherapeuticapproachesforcancertreatment AT hickeyrobertj novelpeptidetherapeuticapproachesforcancertreatment AT malkaslindah novelpeptidetherapeuticapproachesforcancertreatment |